Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Compugen stock

Learn how to easily invest in Compugen stock.

Compugen is a biotechnology business based in the US. Compugen shares (CGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Compugen employs 73 staff and has a trailing 12-month revenue of around $6 million.

How to buy shares in Compugen

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CGEN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Compugen stock price (NASDAQ: CGEN)

Use our graph to track the performance of CGEN stocks over time.

Compugen shares at a glance

Information last updated 2022-10-03.
Latest market close$0.68
52-week range$0.66 - $7.48
50-day moving average $1.24
200-day moving average $2.43
Wall St. target price$9.13
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.40

Buy Compugen shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Compugen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Compugen price performance over time

Historical closes compared with the close of $0.6843 from 2022-10-04

1 week (2022-09-29) 2.13%
1 month (2022-09-06) -34.83%
3 months (2022-07-06) -67.57%
6 months (2022-04-06) -78.94%
1 year (2021-10-06) -89.05%
2 years (2020-10-06) -95.71%
3 years (2019-10-04) 4.29
5 years (2017-10-06) 3.55

Compugen financials

Revenue TTM $6 million
Gross profit TTM $5.3 million
Return on assets TTM -18.63%
Return on equity TTM -34.73%
Profit margin 0%
Book value $1.04
Market capitalisation $66.2 million

TTM: trailing 12 months

Compugen share dividends

We're not expecting Compugen to pay a dividend over the next 12 months.

Compugen share price volatility

Over the last 12 months, Compugen's shares have ranged in value from as little as $0.66 up to $7.48. A popular way to gauge a stock's volatility is its "beta".

CGEN.US volatility(beta: 2.14)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Compugen's is 2.1406. This would suggest that Compugen's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Compugen overview

Compugen Ltd. , a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd.

Frequently asked questions

What percentage of Compugen is owned by insiders or institutions?
Currently 5.681% of Compugen shares are held by insiders and 37.855% by institutions.
How many people work for Compugen?
Latest data suggests 73 work at Compugen.
When does the fiscal year end for Compugen?
Compugen's fiscal year ends in December.
Where is Compugen based?
Compugen's address is: Azrieli Center, Holon, Israel, 5885849
What is Compugen's ISIN number?
Compugen's international securities identification number is: IL0010852080
What is Compugen's CUSIP number?
Compugen's Committee on Uniform Securities Identification Procedures number is: M25722105

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site